Lixiana put up a great fight in NOAC market in beginning of 2nd yearly half
The Lixiana’s growth trend has drawn attention in the novel oral anticoagulant(NOAC) market in the beginning of the 2nd yearly half. The product not only showed an increase rate among other products on July compared to June, but first outran Pradaxa on the 3rd position in the amount of prescripti...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.